Figure 1
Figure 1. Response to treatment assessed by different imaging modalities. (A) Abdominal CT performed before treatment and (B) after 4 years of SRL and PDN treatment in patient #2. The scans show marked shrinkage of peri-renal (arrows) and peri-aortic fibrosis (arrowhead). (C) Cardiac MRI (T2-weighted, fat-saturation sequence, sagittal view) performed before treatment and (D) after 12 months of treatment with SRL and PDN in patient #10. The scans show neither recurrence of pericardial effusion (arrow) (the patient had also undergone pericardiocentesis) nor signs of pericardial infiltration. (E) 18F-FDG PET-CT performed before and (F) after 12 months of treatment with SRL and PDN in patient #10. The scans (axial view) show disappearance of 18F-FDG uptake at the thoracic aorta level (aortic arch) (arrow).

Response to treatment assessed by different imaging modalities. (A) Abdominal CT performed before treatment and (B) after 4 years of SRL and PDN treatment in patient #2. The scans show marked shrinkage of peri-renal (arrows) and peri-aortic fibrosis (arrowhead). (C) Cardiac MRI (T2-weighted, fat-saturation sequence, sagittal view) performed before treatment and (D) after 12 months of treatment with SRL and PDN in patient #10. The scans show neither recurrence of pericardial effusion (arrow) (the patient had also undergone pericardiocentesis) nor signs of pericardial infiltration. (E) 18F-FDG PET-CT performed before and (F) after 12 months of treatment with SRL and PDN in patient #10. The scans (axial view) show disappearance of 18F-FDG uptake at the thoracic aorta level (aortic arch) (arrow).

Close Modal

or Create an Account

Close Modal
Close Modal